<DOC>
	<DOCNO>NCT00014066</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make cnacer cell sensitive light kill tumor cell . Brachytherapy use radiation damage tumor cell . Photodynamic therapy combine brachytherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness photodynamic therapy plus brachytherapy treating patient recurrent lung cancer block lung passage .</brief_summary>
	<brief_title>Photodynamic Therapy Plus Brachytherapy Treating Patients With Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility , toxicity , effectiveness combination therapy Photofrin PDT HDT brachytherapy patient endobronchial obstruction lung cancer . OUTLINE : This randomize study . Photofrin solution administer slowly bolus injection 3-5 minute day 1 . Bronchoscopy perform general anesthesia 48 hour Photofrin injection . Light transmit laser tumor via quartz fiber optic ( interstitial surface PDT ) . Another bronchoscopy perform 48 hour PDT treatment clean tissue debris leave PDT treatment . HDR brachytherapy perform use prescribe dose radiation 5-10 minute designate position . Repeat bronchoscopy perform 3-4 week post HDR brachytherapy second HDR brachytherapy treatment may give . Patients follow every 3 month death , 5 year . PROJECTED ACCRUAL : 16 patient enter 1.5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Hematoporphyrin Derivative</mesh_term>
	<mesh_term>Hematoporphyrins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm small cell nonsmall cell primary lung cancer symptomatic endobronchial lesion ( ) partially totally obstruct airway distal carina accessible endoscopy Recurrent disease follow prior therapy and/or ineligible , refuse , alternative standard therapy : Surgery External radiation therapy Chemotherapy High grade obstruction necessitate rapid aeration palliation standard therapy provide No evidence encasement extension tumor right leave major pulmonary vessel CT chest No tumor involvement trachea carina PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2 time upper limit normal SGOT/SGPT le 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Other : Not pregnant Adequate method contraception require fertile patient Female fertile patient must normal serum beta HCG Not eligible standard therapy and/or protocol therapy No hypersensitivity DHE porphyrins Not concurrent photosensitize drug : Tetracycline Doxorubicin No contraindication general anesthesia , include EKG abnormality suggestive acute ischemia PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No chemotherapy within 3 week prior study entry No doxorubicin within 8 week prior study entry Endocrine therapy : Not specify Radiotherapy : Prior radiation therapy dose high 75 Gy propose bronchial segment allow No concurrent external brain radiation therapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage 0 non-small cell lung cancer</keyword>
</DOC>